Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO)

J Infect. 2024 Aug;89(2):106206. doi: 10.1016/j.jinf.2024.106206. Epub 2024 Jun 17.

Abstract

Objectives: The risk of Post-COVID-19 condition (PCC) under hybrid immunity remains unclear.

Methods: Using data from the German National Cohort (NAKO Gesundheitsstudie), we investigated risk factors for self-reported post-infection symptoms (any PCC is defined as having at least one symptom, and high symptom burden PCC as having nine or more symptoms).

Results: Sixty percent of 109,707 participants reported at least one previous SARS-CoV-2 infection; 35% reported having had any symptoms 4-12 months after infection; among them 23% reported nine or more symptoms. Individuals, who did not develop PCC after their first infection, had a strongly reduced risk for PCC after their second infection (50%) and a temporary risk reduction, which waned over 9 months after the preceding infection. The risk of developing PCC strongly depended on the virus variant. Within variants, there was no effect of the number of preceding vaccinations, apart from a strong protection by the fourth vaccination compared to three vaccinations for the Omicron variant (odds ratio = 0.52; 95% confidence interval 0.45-0.61).

Conclusions: Previous infections without PCC and a fourth vaccination were associated with a lower risk of PCC after a new infection, indicating diminished risk under hybrid immunity. The two components of risk reduction after a preceding infection suggest different immunological mechanisms.

Keywords: Hybrid immunity; Post-COVID-19 condition; Reinfection; SARS-CoV-2; Vaccination.

MeSH terms

  • Adult
  • Aged
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / immunology
  • COVID-19* / epidemiology
  • COVID-19* / immunology
  • Cohort Studies
  • Female
  • Germany / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Post-Acute COVID-19 Syndrome
  • Risk Factors
  • SARS-CoV-2* / immunology
  • Vaccination / statistics & numerical data
  • Young Adult

Substances

  • COVID-19 Vaccines

Supplementary concepts

  • SARS-CoV-2 variants